2.38 USD
▼-0.12-4.80%
盘后 2.38 0.00%
2026-09-16
市值
$8.31M
市盈率
—
EPS
-0.01
股息率
—
52 周区间
2.01 – 10.28
成交量
1.42K
Beta
0.45
目标价
—
52W 低 2.0152W 高 10.28
价格走势
公司简介
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company’s lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies...